Segment Information (Tables)

12 Months Ended

Dec. 31, 2012

Segment Information

Segment Information

as of and for the years ended December 31 (in millions)	BioScience		Medical Products		Other			Total
2012
Net sales		$6,237	$	7,953	$	—		$	14,190
Depreciation and amortization		243		385		84			712
Pre-tax income (loss)		2,309		1,592		(1,012	)		2,889
Assets		7,380		7,568		5,442			20,390
Capital expenditures		570		495		96			1,161
2011
Net sales		$6,053	$	7,840	$	—		$	13,893
Depreciation and amortization		209		341		120			670
Pre-tax income (loss)		2,416		1,522		(1,129	)		2,809
Assets		6,533		7,495		5,045			19,073
Capital expenditures		370		467		123			960
2010
Net sales		$5,640	$	7,203	$	—		$	12,843
Depreciation and amortization		211		401		73			685
Pre-tax income (loss)		2,232		663		(1,005	)		1,890
Assets		6,165		6,604		4,720			17,489
Capital expenditures		410		409		144			963

Pre-Tax Income Reconciliation

Pre-Tax Income Reconciliation

years ended December 31 (in millions)	2012			2011			2010
Total pre-tax income from segments	$	3,901		$	3,938		$	2,895
Unallocated amounts
Net interest expense		(87	)		(54	)		(87	)
Certain foreign exchange fluctuations and hedging activities		53			(16	)		52
Stock compensation		(130	)		(119	)		(120	)
Business optimization charges		(150	)		(192	)		(257	)
AWP litigation and historical price reporting charge		—			(79	)		—
Asset impairment and other charges		—			(103	)		(28	)
Pension settlement charges		(168	)		—			—
Other Corporate items		(530	)		(566	)		(565	)
Consolidated income before income taxes	$	2,889		$	2,809		$	1,890

Assets Reconciliation

Assets Reconciliation

as of December 31 (in millions)	2012		2011
Total segment assets	$	14,948	$	14,028
Cash and equivalents		3,270		2,905
Deferred income taxes		1,500		1,418
PP&E, net		461		464
Other Corporate assets		211		258
Consolidated total assets	$	20,390	$	19,073

Geographic Information

Net sales are based on product shipment destination and assets are based on physical location.

years ended December 31 (in millions)	2012		2011		2010
Net sales
United States	$	6,056	$	5,709	$	5,264
Europe		4,196		4,392		4,188
Asia-Pacific		2,229		2,107		1,873
Latin America and Canada		1,709		1,685		1,518
Consolidated net sales	$	14,190	$	13,893	$	12,843

as of December 31 (in millions)	2012		2011		2010
Total assets
United States	$	8,034	$	7,524	$	6,886
Europe		8,597		8,096		6,789
Asia-Pacific		1,943		1,807		1,577
Latin America and Canada		1,816		1,646		2,237
Consolidated total assets	$	20,390	$	19,073	$	17,489

as of December 31 (in millions)	2012		2011		2010
PP&E, net
United States	$	2,333	$	2,091	$	2,072
Austria		802		786		787
Other countries		2,963		2,648		2,401
Consolidated PP&E, net	$	6,098	$	5,525	$	5,260

Significant Product Sales

The following is a summary of net sales as a percentage of consolidated net sales for the company’s principal product categories.

years ended December 31	2012			2011			2010
Renal1		18	%		18	%		19	%
Recombinants2		16	%		16	%		16	%
Global Injectables3		15	%		14	%		15	%
IV Therapies4		14	%		13	%		13	%
Antibody Therapy5		11	%		11	%		11	%
Plasma Proteins6		10	%		10	%		11	%

¹  Consists of PD and HD therapies.

² Consists of recombinant FVIII therapies.

³  Primarily consists of the company’s enhanced packaging, premixed drugs, pharmacy compounding, pharmaceutical partnering business and generic injectables. The company divested its U.S. multi-source generic injectables business in May 2011.

⁴  Principally includes IV solutions and nutritional products.

⁵  Primarily consists of the company’s liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID).

⁶  Includes plasma-based therapies such as plasma-derived hemophilia (FVII, FVIII and FEIBA), albumin and alpha-1 antitrypsin products.